pfizer patient assistance program inflectra

See more

Does INFLECTRA have copay assistance?

The Pfizer enCompass Co-Pay Assistance Program provides assistance for out-of-pocket drug costs associated with INFLECTRA due to co-pays, co-insurances, or deductibles, up to $20,000 per calendar year. You are responsible for the first $5 of each injection before the benefit may be used.

What is the name of Pfizer's patient assistance program for its infliximab biosimilar in the United States?

INFLECTRA® (infliximab-dyyb) for Healthcare professionals: Inflectra (infliximab – dyyb) for Injection U.S. Physician Prescribing Information.

Does Pfizer have a patient assistance program?

patients in need get access to their Pfizer medicines. Today, Pfizer RxPathways® connects eligible U.S. patients to a range of Pfizer assistance programs that provide insurance support, co-pay help, and medicines for free or at a savings.

What is the cost of INFLECTRA?

SEB infliximab (Inflectra) is available as a 100 mg/vial solution for intravenous infusion at a manufacturer submitted price of $525.00 pervial.

How often do you get INFLECTRA infusions?

The recommended dosage of INFLECTRA is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of adult patients with moderately to severely active UC.

Is INFLECTRA a chemo drug?

Infliximab is a TNF (tumor necrosis factor) blocker. It's used to treat moderate to severe Crohn's disease. It was initially designed as a chemotherapy drug to treat cancer but wasn't effective for cancer. The drug has been shown to work against autoimmune diseases like rheumatoid arthritis and Crohn's.

What is Pfizer PAP connect?

Pfizer PAP Connect is designed to simplify how patients can access certain Pfizer medicines through the Pfizer Patient Assistance Program (PAP).

What is Xelsource?

Psoriatic Arthritis. • XELJANZ/XELJANZ XR (tofacitinib) is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).

What is Pfizer connect?

The Pfizer Patient Assistance Program provides certain medicines for free to eligible financially needy insured and uninsured patients.

What is the success rate of INFLECTRA?

The response rates, 71.4% for INFLECTRA and 75.2% for REMICADE,1 were not statistically significantly different. INFLECTRA is marketed as INFLECTRA (infliximab-dyyb) in the UnitedStates (U.S.) and under other brand names in some countries.

Is INFLECTRA safer than Remicade?

Remicade and Inflectra help block TNF-alpha to lower inflammation in your body. Because of their many similarities, there aren't any clinically meaningful safety or effectiveness differences between them. They're both safe and effective treatment options for many autoimmune disorders.

Is INFLECTRA cheaper than Remicade?

Inflectra, as a biosimilar, is slightly less expensive than Remicade. Inflectra costs about $997 per 100 mg vial while Remicade costs about $1,229 for the same amount.

What is Xelsource?

Psoriatic Arthritis. • XELJANZ/XELJANZ XR (tofacitinib) is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).

What is the purpose of Paxlovid?

Paxlovid is an oral antiviral pill that can be taken at home to help keep high-risk patients from getting so sick that they need to be hospitalized. So, if you test positive for the coronavirus and you are eligible to take the pills, you can take them at home and lower your risk of going to the hospital.

What is Pfizer connect?

The Pfizer Patient Assistance Program provides certain medicines for free to eligible financially needy insured and uninsured patients.

What is Pfizer PAP connect?

Pfizer PAP Connect is designed to simplify how patients can access certain Pfizer medicines through the Pfizer Patient Assistance Program (PAP).

What is Inflectra used for?from accessdata.fda.gov

Inflectra is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.

How long does it take to take Inflectra?from drugs.com

The recommended dose of Inflectra is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of chronic severe (i.e., extensive and/or disabling) plaque psoriasis.

How long does infliximab last?from accessdata.fda.gov

The safety and efficacy of infliximab in patients with juvenile rheumatoid arthritis (JRA) were evaluated in a multicenter, randomized, placebo-controlled, double-blind study for 14 weeks, followed by a double-blind, all-active treatment extension, for a maximum of 44 weeks. Patients with active JRA between the ages of 4 and 17 years who had been treated with MTX for at least 3 months were enrolled. Concurrent use of folic acid, oral corticosteroids (≤0.2 mg/kg/day of prednisone or equivalent), NSAIDs, and/or disease modifying antirheumatic drugs (DMARDs) was permitted.

What are the malignancies associated with TNF blockers?from accessdata.fda.gov

The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months (range 1 to 84 months) after the first dose of TNF blocker therapy. Most of the patients were receiving concomitant immunosuppressants. These cases were reported postmarketing and are derived from a variety of sources, including registries and spontaneous postmarketing reports.

How long does it take for Infliximab to cause hypersensitivity?from drugs.com

Most hypersensitivity reactions (including anaphylaxis, urticaria, dyspnea, and/or hypotension), have occurred during or within 2 hours of infliximab product infusion.

How safe is Infliximab?from drugs.com

The safety and effectiveness of infliximab products for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients aged 6 years and older with moderately to severely active UC who have had an inadequate response to conventional therapy are supported by evidence from adequate and well-controlled studies of infliximab in adults. Additional safety and pharmacokinetic data were collected in an open-label pediatric UC trial in 60 pediatric patients aged 6 through 17 years (median age 14.5 years) with moderately to severely active UC (Mayo score of 6 to 12; Endoscopic subscore ≥2) and an inadequate response to conventional therapies. At baseline, the median Mayo score was 8, 53% of patients were receiving immunomodulator therapy (6-MP/AZA/MTX), and 62% of patients were receiving corticosteroids (median dose 0.5 mg/kg/day in prednisone equivalents). Discontinuation of immunomodulators and corticosteroid taper were permitted after Week 0.

What infections are treated with Infliximab?from accessdata.fda.gov

The infections most frequently reported were respiratory tract infections (including sinusitis, pharyngitis, and bronchitis) and urinary tract infections. Among patients treated with infliximab, serious infections included pneumonia, cellulitis, abscess, skin ulceration, sepsis, and bacterial infection. In clinical trials, 7 opportunistic infections were reported; 2 cases each of coccidioidomycosis (1 case was fatal) and histoplasmosis (1 case was fatal), and 1 case each of pneumocystosis, nocardiosis and cytomegalovirus. Tuberculosis was reported in 14 patients, 4 of whom died due to miliary tuberculosis. Other cases of tuberculosis, including disseminated tuberculosis, also have been reported postmarketing. Most of these cases of tuberculosis occurred within the first 2 months after initiation of therapy with infliximab and may reflect recrudescence of latent disease [see Warnings and Precautions (5.1)]. In the 1-year placebo-controlled studies RA I and RA II, 5.3% of patients receiving infliximab every 8 weeks with methotrexate (MTX) developed serious infections as compared to 3.4% of placebo patients receiving MTX. Of 924 patients receiving infliximab, 1.7% developed pneumonia and 0.4% developed tuberculosis, when compared to 0.3% and 0.0% in the placebo arm respectively. In a shorter (22-week) placebo-controlled study of 1082 RA patients randomized to receive placebo, 3 mg/kg or 10 mg/kg infusions with infliximab at 0, 2, and 6 weeks, followed by every 8 weeks with MTX, serious infections were more frequent in the 10 mg/kg infliximab group (5.3%) than the 3 mg/kg or placebo groups (1.7% in both). During the 54-week Crohn's II Study, 15% of patients with fistulizing Crohn's disease developed a new fistula-related abscess.